Archives — January 2018 back to current month (13)
Medical Device Firm Boosts Quarterly Revenue 50% YOY (01/31/2018)
A Maxim Group report noted the recently announced revenue achieved and anticipated by this producer of cancer treatment devices.
Jason Kolbert, an analyst with Maxim Group, explained the drivers behind adding this drug and drug delivery developer to his coverage universe.
H.C. Wainwright & Co. reported on the significance of preliminary data for treatments for head and neck cancer, as well as for cervical cancer.
Pancreatic Cancer Trial Data Will Be Released Soon (01/24/2018)
A biotech company that has begun clinical testing of human antibodies to treat cancers is in discussion with potential partners.
André Uddin, an analyst with Mackie Research Capital Corp., shared his thesis for investing in this biotech.
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance in Asia.
Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status.
One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment.
André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug.
As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.
Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors.
A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts.
Portfolio Manager's Biotech Watchlist Picks for 2018 (01/02/2018)
StoneCastle Investment Management has a high-growth fund that invests wherever it finds opportunities, and it is bullish on healthcare. In this interview with The Life Sciences Report, portfolio manager Bruce Campbell highlights four companies that he is putting on Streetwise Reports' 2018 Biotech Watchlist.
|"We continue to view DRRX as undervalued and reiterate our Buy rating."|
|"SPR's acquisition in the pipeline creates water-soluble cannabis."|
|"We are initiating coverage on PMN."|